Wed, March 5, 2025
Tue, March 4, 2025
Mon, March 3, 2025
Sun, March 2, 2025
Sat, March 1, 2025
Fri, February 28, 2025
Sun, February 23, 2025
Sat, February 22, 2025

Johnson & Johnson (JNJ): Among the Best Psychedelic Stocks to Buy in 2025


  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. -the-best-psychedelic-stocks-to-buy-in-2025.html
  Print publication without navigation Published in Business and Finance on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source


  We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic stocks.

The article from MSN Money discusses Johnson & Johnson (JNJ) as one of the top psychedelic stocks to consider for investment in 2025. It highlights the growing interest in psychedelic medicine for treating mental health issues like depression, anxiety, and PTSD. Johnson & Johnson has been involved in this sector through its pharmaceutical division, particularly with the development of Spravato (esketamine), which has been approved by the FDA for treatment-resistant depression. The article notes that while J&J isn't solely focused on psychedelics, its involvement in this emerging market, combined with its robust financial health and diversified portfolio, makes it an attractive option for investors looking at the psychedelic industry. The piece also mentions other companies like Compass Pathways and Atai Life Sciences, but emphasizes J&J's established presence and resources as a significant advantage.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/other/johnson-johnson-jnj-among-the-best-psychedelic-stocks-to-buy-in-2025/ar-AA1A3MoP ]

Publication Contributing Sources